측방유동 어세이 시장 규모, 점유율, 동향 분석 보고서 : 제품별, 방법별, 최종 용도별, 시험별, 최종 용도별, 지역별, 부문별 예측(2025-2030년)

Lateral Flow Assays Market Growth & Trends:

The global lateral flow assays market size is estimated to reach USD 13.60 billion by 2030, expanding at a CAGR of 5.99% from 2025 to 2030, according to a new report by Grand View Research, Inc. Major factors driving the growth include the rising prevalence of infectious diseases, growing government initiatives to curb infectious and chronic diseases, rise in demand for point-of-care testing, and increasing strategic mergers & acquisitions among others.

Lateral flow assays were developed about half a century ago and have facilitated several diagnostic and testing applications in domains such as healthcare, food & beverage testing, and environmental testing. Similarly, lateral flow assay applications in point-of-care diagnostics are growing and are propelling significant advancements in research for the development of products that evaluate body fluids, such as urine and saliva.

The use of these devices promotes self-testing, reduces the need for laboratory testing, and eliminates the need for trained laboratory personnel. Although there have been several technological advancements in laboratory testing in the recent past, several emerging economies still face challenges regarding timely medical intervention. This represents a major factor that is driving the adoption of dipsticks or lateral flow assays for facilitating timely diagnosis and treatment.

Due to the increasing utility of lateral flow assays for home use and self-testing, several at-home tests were launched after the pandemic began. For instance, tests such as Abbott's BinaxNOW COVID-19 Antigen Self-Test, Access Bio's CareStart COVID-19 Antigen Home Test, Becton, Dickinson and Company's BD Veritor At-Home COVID-19 Test, and Ellume's COVID-19 Home Test are commercially available.

Government initiatives supporting the use of such tests are expected to enhance the penetration of lateral flow assays and can aid in driving the lateral flow assays market growth. For instance, the Biden-Harris administration has incentivized health plans and insurers for installing a network of locations across the country for providing at-home, over-the-counter COVID-19 tests for free to people with private health coverage.

Continuous strategic initiatives undertaken by leading and emerging players to develop and launch advanced products are anticipated to significantly support market growth. For instance, in November 2021, IUL SA launched the iPeak Europium, a new lateral flow reader used to scan fluorescence-labeled lateral flow tests. Similarly, in March 2021, the company introduced its new lateral flow reader, iPeak+.

Additionally, in January 2021, Sensyne Health, based in the U.K., introduced an innovative smartphone app-MagnifEye-that employs deep machine learning AI to automate the interpretation of lateral flow diagnostic tests. A rise in mergers and collaborations by market players is anticipated to facilitate access to novel lateral flow technologies.

For instance, in February 2022, U.S.-based BD (Becton, Dickinson and Company) and Scanwell Health collaborated to create an at-home rapid test for SARS-CoV-2 using a BD lateral flow antigen test and the Scanwell Health mobile app. The collaboration aims to provide an efficient and scalable rapid antigen home testing solution.

The use of lateral flow devices also eliminates the need to wait for deciphering test results as well as aids in the optimization of timely treatment decisions, improves the efficacy of care provided, and significantly reduces diagnosis costs, especially in areas with resource-constrained settings and insufficient laboratory infrastructure. The rising trend of decentralized testing has been crucial in increasing the adoption of lateral flow devices globally.

The role of these devices has also been observed in controlling major infectious diseases such as malaria and influenza. According to WHO, rapid diagnostic tests are used in diagnosis by healthcare professionals distant from microscopy services; remote diagnosis by professionals in malaria54-endemic countries; and outbreak investigation & survey of parasite prevalence. Thus, various benefits offered by lateral flow devices are among the key factors responsible for increasing the adoption of lateral flow assays globally.

On the other hand, with the advent of advanced technologies, such as PCR and molecular diagnostics, the demand for lateral flow assays may be witnessing sluggish growth to a certain extent. Although lateral flow assays have high specificity and sensitivity, PCR and other molecular diagnostic technologies have emerged to be more sensitive.

Lateral Flow Assays Market Report Highlights:

• Kits & reagents dominated the market share of 35.43% in 2024. These products offer versatility for use in pharmaceuticals, animal health, environmental testing, feed & food testing, and crop & plant testing
• The launch of new self-testing and at-home kits by major players is anticipated to boost market growth during the forecast period. For instance, in July 2021, Abbott Laboratories launched its Panbio COVID-19 Antigen Self-Test in India, which was followed by Roche Diagnostics India's launch of its COVID-19 At-Home Test in January 2022
• In 2024, the clinical testing segment led the market, driven by a surge in infectious diseases and heightened demand for rapid, accurate test kits. Lateral flow assays are used in clinical testing by multiple diagnostic facilities due to ease of use & portability. These tests offer results with a reduced turnaround time as compared to other laboratory tests. In addition, as oral fluid-based testing is gradually developing, the use of lateral flow assays is becoming convenient because of the noninvasive nature of collecting specimens
• Sandwich assays dominated the global market in 2024 due to their high accuracy, cost-effectiveness, and ease of use, owing to their affordability, accuracy, and ease of use. These assays can also be performed in low-resource healthcare settings without the need for prior training. As a result, sandwich assays are widely used, which drives the growth
• The lateral flow immunoassay segment dominated the global market in 2024. These assays can be used for the detection of antigens or antibodies in clinical samples and offer an effective diagnostic option that conforms with the WHO ASSURED criteria for diagnostics. With increasing requirements for point-of-care testing alternatives in recent years, the demand for such assays is projected to grow over the forecast period
• In 2024, the hospitals and clinics segment captured a significant market share, as these primary care settings remain essential for diagnosing, treating, and managing a wide range of medical conditions. The increasing need for hospitals with enhanced diagnostic services and rising global healthcare expenditure are anticipated to fuel market growth
• Various infectious diseases, such as influenza, HIV, and hepatitis, are easily transmitted in hospitals, often causing outbreaks. To reduce or even eliminate such occurrences, hospitals have to comply with specific guidelines to ensure adequate patient quarantine measures, the safety of healthcare workers, and proper sanitization
• North America held the dominant revenue share of 35.43% in 2024, owing to an increase in the incidence of infectious diseases such as influenza. For instance, as per the U.S. CDC estimates, between 2010 and 2020, there have been around 9 million to 41 million influenza infection cases, leading to about 140,000 to 710,000 hospitalizations and 12,000 to 52,000 deaths annually in the U.S.
• Asia Pacific lateral flow assays industry is anticipated to grow at the fastest CAGR over the forecast period owing to increasing collaborations among market entrants and a rise in product approval for various infectious disease tests is anticipated to boost the growth. For instance, in February 2020, Shenzen Bioeasy Biotechnology announced that the company received CE marking for its COVID-19 LFA immunoassay kits

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation and Scope
• 1.2. Market Definitions
• 1.3. Research Methodology
  • 1.3.1. Information Procurement
  • 1.3.2. Information or Data Analysis
  • 1.3.3. Market Formulation & Data Visualization
  • 1.3.4. Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Lateral Flow Assay Market Variables, Trends, & Scope

• 3.1. Market Introduction/Lineage Outlook
• 3.2. Market Size and Growth Prospects (USD Million)
• 3.3. Market Dynamics
  • 3.3.1. Market Drivers Analysis
    • 3.3.1.1. Increasing prevalence of infectious diseases
    • 3.3.1.2. Technological advancements in lateral flow
    • 3.3.1.3. Growing adoption in homecare settings
  • 3.3.2. Market Restraints Analysis
    • 3.3.2.1. Stringent Regulations
  • 3.3.3. Market Opportunities Analysis
    • 3.3.3.1. Growing demand for Point-of-Care (POC) Testing
    • 3.3.3.2. Expanding applications beyond healthcare
  • 3.3.4. Market Challenges Analysis
    • 3.3.4.1. Product Recalls
• 3.4. Lateral Flow Assay Market Analysis Tools
  • 3.4.1. Porter's Analysis
    • 3.4.1.1. Bargaining power of the suppliers
    • 3.4.1.2. Bargaining power of the buyers
    • 3.4.1.3. Threats of substitution
    • 3.4.1.4. Threats from new entrants
    • 3.4.1.5. Competitive rivalry
  • 3.4.2. PESTEL Analysis
    • 3.4.2.1. Political landscape
    • 3.4.2.2. Economic and Social landscape
    • 3.4.2.3. Technological landscape
    • 3.4.2.4. Environmental landscape
    • 3.4.2.5. Legal landscape
  • 3.4.3. Pipeline
  • 3.4.4. Case Study

Chapter 4. Lateral Flow Assay Market: Product Estimates & Trend Analysis

• 4.1. Lateral Flow Assay Market: Product Movement Analysis
• 4.2. Lateral Flow Assay Market Estimates and Forecasts, by Product 2024 & 2030 (USD Million)
• 4.3. Kits & Reagents
  • 4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.4. Lateral Flow Readers
  • 4.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.2. Benchtop Readers
    • 4.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4.3. Digital Readers
    • 4.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Lateral Flow Assay Market: Application Estimates & Trend Analysis

• 5.1. Lateral Flow Assay Market: Application Movement Analysis
• 5.2. Lateral Flow Assay Market Estimates and Forecasts, by Application 2024 & 2030 (USD Million)
• 5.3. Clinical Testing
  • 5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.2. Infectious Disease Testing
    • 5.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.2. COVID-19
      • 5.3.2.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.3. Mosquito Borne Disease Testing
      • 5.3.2.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.4. Influenza Testing
      • 5.3.2.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.5. Sexually Transmitted Infection Testing
      • 5.3.2.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.5.2. HIV Testing
        • 5.3.2.5.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.5.3. HPV Testing
        • 5.3.2.5.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.5.4. Chlamydia Testing
        • 5.3.2.5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.5.5. Gonorrhea Testing
        • 5.3.2.5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.5.6. Syphilis Testing
        • 5.3.2.5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
      • 5.3.2.5.7. Other STI Testing
        • 5.3.2.5.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.6. Hepatitis
      • 5.3.2.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.7. Tuberculosis
      • 5.3.2.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.2.8. Other Infectious Diseases
      • 5.3.2.8.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.3. Cardiac Marker Testing
    • 5.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3.2. Troponin I and T Testing
      • 5.3.3.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3.3. CK-MB Testing
      • 5.3.3.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3.4. BNP and NT-Probnp Testing
      • 5.3.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3.5. Myoglobin Testing
      • 5.3.3.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3.6. D-Dimer Testing
      • 5.3.3.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.3.7. Other Cardiac Marker Tests
      • 5.3.3.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.4. Pregnancy & Fertility Testing
    • 5.3.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4.2. Pregnancy Testing
      • 5.3.4.2.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 5.3.4.3. Fertility Testing
      • 5.3.4.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.5. Cholesterol Testing/Lipid Profile
    • 5.3.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.6. Drugs of Abuse Testing
    • 5.3.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.3.7. Other Clinical Tests
    • 5.3.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.4. Veterinary Diagnostics
  • 5.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Food Safety & Environment Testing
  • 5.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.6. Drug Development & Quality Testing
  • 5.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Lateral Flow Assay Market: Technique Estimates & Trend Analysis

• 6.1. Lateral Flow Assay Market: Technique Movement Analysis
• 6.2. Lateral Flow Assay Market Estimates and Forecasts, by Technique 2024 & 2030 (USD Million)
• 6.3. Sandwich Assays
  • 6.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.4. Competitive Assays
  • 6.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Multiplex Detection Assays
  • 6.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Lateral Flow Assay Market: Test Estimates & Trend Analysis

• 7.1. Lateral Flow Assay Market: Test Movement Analysis
• 7.2. Lateral Flow Assay Market Estimates and Forecasts, by Test 2024 & 2030 (USD Million)
• 7.3. Lateral Flow Immunoassay
  • 7.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.4. Nucleic Acid Lateral Flow Assay
  • 7.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Lateral Flow Assay Market: End Use Estimates & Trend Analysis

• 8.1. Lateral Flow Assay Market: End Use Movement Analysis
• 8.2. Lateral Flow Assay Market Estimates and Forecasts, by End Use 2024 & 2030 (USD Million)
• 8.3. Hospitals & Clinics
  • 8.3.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.4. Diagnostic Laboratories
  • 8.4.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Home Care
  • 8.5.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Pharmaceutical & Biotechnology Companies
  • 8.6.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Other End Use
  • 8.7.1. Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Lateral Flow Assay Market: Regional Estimates & Trend Analysis

• 9.1. Lateral Flow Assay Market Share, By Region, 2024 & 2030 (USD Million)
• 9.2. North America
  • 9.2.1. North America Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.2. U.S.
    • 9.2.2.1. Key Country Dynamics
    • 9.2.2.2. Competitive Scenario
    • 9.2.2.3. Regulatory Framework
    • 9.2.2.4. Reimbursement Scenario
    • 9.2.2.5. U.S. Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.3. Canada
    • 9.2.3.1. Key Country Dynamics
    • 9.2.3.2. Competitive Scenario
    • 9.2.3.3. Regulatory Framework
    • 9.2.3.4. Reimbursement Scenario
    • 9.2.3.5. Canada Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.2.4. Mexico
    • 9.2.4.1. Key Country Dynamics
    • 9.2.4.2. Competitive Scenario
    • 9.2.4.3. Regulatory Framework
    • 9.2.4.4. Reimbursement Scenario
    • 9.2.4.5. Mexico Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.3. Europe
  • 9.3.1. Europe Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.2. UK
    • 9.3.2.1. Key Country Dynamics
    • 9.3.2.2. Competitive Scenario
    • 9.3.2.3. Regulatory Framework
    • 9.3.2.4. Reimbursement Scenario
    • 9.3.2.5. UK Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.3. Germany
    • 9.3.3.1. Key Country Dynamics
    • 9.3.3.2. Competitive Scenario
    • 9.3.3.3. Regulatory Framework
    • 9.3.3.4. Reimbursement Scenario
    • 9.3.3.5. Germany Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.4. France
    • 9.3.4.1. Key Country Dynamics
    • 9.3.4.2. Competitive Scenario
    • 9.3.4.3. Regulatory Framework
    • 9.3.4.4. Reimbursement Scenario
    • 9.3.4.5. France Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.5. Italy
    • 9.3.5.1. Key Country Dynamics
    • 9.3.5.2. Competitive Scenario
    • 9.3.5.3. Regulatory Framework
    • 9.3.5.4. Reimbursement Scenario
    • 9.3.5.5. Italy Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.6. Spain
    • 9.3.6.1. Key Country Dynamics
    • 9.3.6.2. Competitive Scenario
    • 9.3.6.3. Regulatory Framework
    • 9.3.6.4. Reimbursement Scenario
    • 9.3.6.5. Spain Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.7. Denmark
    • 9.3.7.1. Key Country Dynamics
    • 9.3.7.2. Competitive Scenario
    • 9.3.7.3. Regulatory Framework
    • 9.3.7.4. Reimbursement Scenario
    • 9.3.7.5. Denmark Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.8. Sweden
    • 9.3.8.1. Key Country Dynamics
    • 9.3.8.2. Competitive Scenario
    • 9.3.8.3. Regulatory Framework
    • 9.3.8.4. Reimbursement Scenario
    • 9.3.8.5. Sweden Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.3.9. Norway
    • 9.3.9.1. Key Country Dynamics
    • 9.3.9.2. Competitive Scenario
    • 9.3.9.3. Regulatory Framework
    • 9.3.9.4. Reimbursement Scenario
    • 9.3.9.5. Norway Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.4. Asia Pacific
  • 9.4.1. Asia Pacific Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.2. Japan
    • 9.4.2.1. Key Country Dynamics
    • 9.4.2.2. Competitive Scenario
    • 9.4.2.3. Regulatory Framework
    • 9.4.2.4. Reimbursement Scenario
    • 9.4.2.5. Japan Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.3. China
    • 9.4.3.1. Key Country Dynamics
    • 9.4.3.2. Competitive Scenario
    • 9.4.3.3. Regulatory Framework
    • 9.4.3.4. Reimbursement Scenario
    • 9.4.3.5. China Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.4. India
    • 9.4.4.1. Key Country Dynamics
    • 9.4.4.2. Competitive Scenario
    • 9.4.4.3. Regulatory Framework
    • 9.4.4.4. Reimbursement Scenario
    • 9.4.4.5. India Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.5. Australia
    • 9.4.5.1. Key Country Dynamics
    • 9.4.5.2. Competitive Scenario
    • 9.4.5.3. Regulatory Framework
    • 9.4.5.4. Reimbursement Scenario
    • 9.4.5.5. Australia Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.6. South Korea
    • 9.4.6.1. Key Country Dynamics
    • 9.4.6.2. Competitive Scenario
    • 9.4.6.3. Regulatory Framework
    • 9.4.6.4. Reimbursement Scenario
    • 9.4.6.5. South Korea Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.4.7. Thailand
    • 9.4.7.1. Key Country Dynamics
    • 9.4.7.2. Competitive Scenario
    • 9.4.7.3. Regulatory Framework
    • 9.4.7.4. Reimbursement Scenario
    • 9.4.7.5. Thailand Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.5. Latin America
  • 9.5.1. Latin America Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.2. Brazil
    • 9.5.2.1. Key Country Dynamics
    • 9.5.2.2. Competitive Scenario
    • 9.5.2.3. Regulatory Framework
    • 9.5.2.4. Reimbursement Scenario
    • 9.5.2.5. Brazil Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.5.3. Argentina
    • 9.5.3.1. Key Country Dynamics
    • 9.5.3.2. Competitive Scenario
    • 9.5.3.3. Regulatory Framework
    • 9.5.3.4. Reimbursement Scenario
    • 9.5.3.5. Argentina Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 9.6. Middle East and Africa
  • 9.6.1. Middle East and Africa Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.2. South Africa
    • 9.6.2.1. Key Country Dynamics
    • 9.6.2.2. Competitive Scenario
    • 9.6.2.3. Regulatory Framework
    • 9.6.2.4. Reimbursement Scenario
    • 9.6.2.5. South Africa Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.3. Saudi Arabia
    • 9.6.3.1. Key Country Dynamics
    • 9.6.3.2. Competitive Scenario
    • 9.6.3.3. Regulatory Framework
    • 9.6.3.4. Reimbursement Scenario
    • 9.6.3.5. Saudi Arabia Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.4. UAE
    • 9.6.4.1. Key Country Dynamics
    • 9.6.4.2. Competitive Scenario
    • 9.6.4.3. Regulatory Framework
    • 9.6.4.4. Reimbursement Scenario
    • 9.6.4.5. UAE Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 9.6.5. Kuwait
    • 9.6.5.1. Key Country Dynamics
    • 9.6.5.2. Competitive Scenario
    • 9.6.5.3. Regulatory Framework
    • 9.6.5.4. Reimbursement Scenario
    • 9.6.5.5. Kuwait Lateral Flow Assay Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 10. Competitive Landscape

• 10.1. Recent Developments & Impact Analysis by Key Market Participants
• 10.2. Company Categorization
• 10.3. Company Heat Map Analysis
• 10.4. Company Profiles
  • 10.4.1. Abbott
    • 10.4.1.1. Participant's Overview
    • 10.4.1.2. Financial Performance
    • 10.4.1.3. Product Benchmarking
    • 10.4.1.4. Recent Developments/ Strategic Initiatives
  • 10.4.2. Bio-Rad Laboratories, Inc
    • 10.4.2.1. Participant's Overview
    • 10.4.2.2. Financial Performance
    • 10.4.2.3. Product Benchmarking
    • 10.4.2.4. Recent Developments/ Strategic Initiatives
  • 10.4.3. Siemens Healthineers AG
    • 10.4.3.1. Participant's Overview
    • 10.4.3.2. Financial Performance
    • 10.4.3.3. Product Benchmarking
    • 10.4.3.4. Recent Developments/ Strategic Initiatives
  • 10.4.4. BIOMERIEUX
    • 10.4.4.1. Participant's Overview
    • 10.4.4.2. Financial Performance
    • 10.4.4.3. Product Benchmarking
    • 10.4.4.4. Recent Developments/ Strategic Initiatives
  • 10.4.5. BD
    • 10.4.5.1. Participant's Overview
    • 10.4.5.2. Financial Performance
    • 10.4.5.3. Product Benchmarking
    • 10.4.5.4. Recent Developments/ Strategic Initiatives
  • 10.4.6. QIAGEN
    • 10.4.6.1. Participant's Overview
    • 10.4.6.2. Financial Performance
    • 10.4.6.3. Product Benchmarking
    • 10.4.6.4. Recent Developments/ Strategic Initiatives
  • 10.4.7. QuidelOrtho Corporation
    • 10.4.7.1. Participant's Overview
    • 10.4.7.2. Financial Performance
    • 10.4.7.3. Product Benchmarking
    • 10.4.7.4. Recent Developments/ Strategic Initiatives
  • 10.4.8. F. Hoffmann-La Roche
    • 10.4.8.1. Participant's Overview
    • 10.4.8.2. Financial Performance
    • 10.4.8.3. Product Benchmarking
    • 10.4.8.4. Recent Developments/ Strategic Initiatives
  • 10.4.9. DH Life Sciences, LLC.
    • 10.4.9.1. Participant's Overview
    • 10.4.9.2. Financial Performance
    • 10.4.9.3. Product Benchmarking
    • 10.4.9.4. Recent Developments/ Strategic Initiatives
  • 10.4.10. Quest Diagnostics
    • 10.4.10.1. Participant's Overview
    • 10.4.10.2. Financial Performance
    • 10.4.10.3. Product Benchmarking
    • 10.4.10.4. Recent Developments/ Strategic Initiatives